Alvotech Shares Drop After FDA Issues Form 483 Post-Inspection
The biotech firm received manageable observations from a routine FDA inspection but remains on track for BLA resubmissions in Q2 2026. Alvotech (NASDAQ:ALVO) disclosed the FDA issued a Form 483 following a routine inspection of its Reykjavik manufacturing facility on May 8